AstraZeneca and GSK: A Comparison of UK Healthcare Stocks Using AI

Overview:

• AstraZeneca: A stronger innovation-focused investment case backed by robust growth, oncology momentum, and extensive AI integration.

• GSK: A value-oriented opportunity defined by higher income, steady specialty medicine expansion, and a growing pipeline.

• AI Strategy: Both pharmaceutical firms utilize artificial intelligence for drug discovery, though AstraZeneca maintains the more expansive footprint.

AstraZeneca and GSK present investors with two distinct approaches to healthcare exposure. The former features an accelerated growth trajectory, a massive oncology portfolio, an extensive drug pipeline, and a comprehensive AI strategy. Conversely, GSK provides a compelling income case with lower market expectations, prominent vaccine and HIV franchises, and a major initiative to rebuild its drug pipeline. Ultimately, the central question is which firm can utilize AI to produce better drugs, higher sales, and increased profitability.

AstraZeneca has a Stronger Growth Profile

AstraZeneca commenced the second half of 2026 riding solid financial momentum. First-half revenues reached USD 30.7 billion, representing a 6% increase at constant exchange rates, while core earnings per share advanced by 11%. Oncology served as the primary growth catalyst, generating USD 14.1 billion in revenue (up 15%), alongside an 11% increase in rare disease revenue.

This performance grants AstraZeneca a distinct edge for investors prioritizing long-term expansion. Management is targeting USD 80 billion in total revenue by 2030, a substantial step up from USD 58.7 billion in 2025. The company’s pipeline currently encompasses 183 projects, which includes 21 late-stage new molecular entities.

Market valuation reflects a different trend. AstraZeneca closed at roughly POUND 119.62 on October 7, 2026, sitting about 6.4% lower year-over-year and roughly 24% beneath its 52-week peak of POUND 157.32. This pullback establishes a more attractive entry point, albeit with the caveat that the stock maintains elevated expectations regarding pipeline delivery.

AI Gives AstraZeneca Another Advantage

Artificial intelligence sits near the core of AstraZeneca’s research framework. Over 90% of its small-molecule discovery pipeline incorporates AI support, and more than 600 data science and AI professionals operate across its research divisions.

The enterprise also leverages its MILTON AI platform to analyze health data, successfully identifying over 1,000 conditions that may display early indicators 10 to 15 years prior to clinical diagnosis. Furthermore, AstraZeneca has partnered with Owkin in a three-year agreement for specialized AI agents while broadening genomic data initiatives alongside Helix.

The advantages of this approach extend far beyond administrative automation. AI assists researchers in pinpointing drug targets, evaluating molecules, examining patient data, and refining clinical trial layouts. Enhancing the research workflow raises the probability of therapeutic success—a vital factor in an industry where a single late-stage clinical failure can incur billions in losses.

Also Read – How Medical Industry is Scaling AI in Healthcare

GSK Offers a Different Investment Case

GSK exhibits a more modest growth rate, yet recent financials demonstrate tangible headway. Second-quarter sales rose 5% to POUND 8.4 billion, propelled by a 14% increase in Specialty Medicines, a 17% jump in oncology sales, a 10% gain in HIV, and an 8% rise in vaccines. Core operating profit grew 7%, while core earnings per share rose 9%.

Additionally, GSK anticipates initiating over 20 Phase III clinical trials in 2026, exceeding its prior target of 10. The company supports 62 clinical-development assets and has transitioned seven assets across 18 indications into accelerated development pathways.

Such pipeline efforts are critical for GSK as it confronts upcoming patent expirations, notably concerning dolutegravir between 2028 and 2030. Accelerated research productivity can help mitigate this impending revenue gap.

GSK Also has a Serious AI Strategy 

While GSK’s scale of AI deployment is smaller than AstraZeneca’s, its strategy remains purposeful. The organization collaborates with Cerebras to apply AI analytics to extensive epigenomic data repositories. Viewing human genetics as a formidable mechanism for drug discovery, GSK notes that genetically validated targets possess roughly double the success rate.

GSK also secured a research partnership with Relation Therapeutics valued at up to USD 110 million, centering on human-cell data and machine learning models designed to discover novel drug targets.

This framework aligns directly with GSK’s primary objective. Given its already established commercial footprint, the key hurdle is generating enough innovative therapeutics to sustain future growth. Superior target identification should enhance the efficiency of its research expenditures.

Also Read – Why Healthcare Needs to Prep Now for Autonomous AI Agents

The Choice Comes Down to Growth or Value

AstraZeneca appeals more directly to investors seeking high growth and exposure to advanced drug discovery methodologies. Its oncology portfolio, rare disease sector, expansive pipeline, and substantial AI investments forge a formidable profile.

Conversely, GSK presents an alternative balance. The stock delivers robust cash generation, a projected 2026 dividend of 69.3 pence, and a share price hovering around POUND 17.91, translating to an approximate 3.9% dividend yield. GSK also retains potential for valuation re-rating should its clinical pipeline yield favorable outcomes.

The next major catalyst approaches in late October. GSK is scheduled to deliver third-quarter earnings on October 28, followed by AstraZeneca on October 30. These updates will provide sharper insight into sales trends, pipeline advancements, and executive outlooks.

Within the realm of AI-driven healthcare, AstraZeneca currently maintains the superior standing. Nonetheless, GSK represents an appealing value proposition if its pipeline strategy successfully delivers a steady stream of viable medicines. Ultimately, the fundamental distinction remains: AstraZeneca operates an established growth engine, whereas GSK relies on its current research investments to build the next phase of expansion.

FAQs